Exact Sciences, a leader in cancer screening and diagnostics, has announced an expanded partnership with Humana, making the Cologuard Plus™ test an in-network service for eligible Humana Medicare Advantage members nationwide starting in August 2025. This collaboration significantly enhances access to a crucial screening tool for Humana's vast network of approximately 5.8 million Medicare Advantage members. Cologuard Plus is a new, FDA-approved, non-invasive colorectal cancer screening test developed in collaboration with the Mayo Clinic, building on the success of the original Cologuard, which has been used over 20 million times since its launch in 2014. The updated test incorporates novel biomarkers and improved laboratory processes, leading to an expected reduction in false positives by more than 40% compared to the original, and has a high specificity of 94%. This increased accuracy helps minimize unnecessary and potentially burdensome follow-up colonoscopies. The Cologuard Plus test is a first-line screening option for average-risk adults aged 45 and older and is included in the U.S. Preventive Services Task Force guidelines. This partnership underscores a shared commitment between Exact Sciences and Humana to remove barriers to care and advance earlier cancer detection, when treatment is most effective, ultimately improving patient outcomes and public health.